EUVIMEDEUVIMED entdecken
Crossref

Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma

Adwitiya Kar, Tapahsama Banerjee, Nikita Pozdeyev iD, Tessa B Holmstoen, Lindsey J Foust, Stacey M Bagby, Todd M Pitts, Mouhammed Amir Habra, Margaret E Wierman iD, Katja Kiseljak-Vassiliades iD

Endocrinology · 2026

DOI: 10.1210/endocr/bqag091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2026. Verfasst von Adwitiya Kar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Veterans Affairs, NCI NIH HHS, Cancer League of Colorado.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Adrenocortical carcinoma (ACC) is an aggressive malignancy with no approved targeted therapy and poor outcomes.

Methods

Using multiple patient-derived xenograft (PDX) and cell line xenograft (CLX) models, and a newly developed PDX model (CUACC9), we investigated the potential action of the multikinase inhibitor OTSSP167 for treatment of ACC.

Results

OTSSP167 effectively reduced tumor growth in wild-type TP53 (CUACC1) and mutant TP53 (H295R, CUACC9) in vivo tumor models. Immunohistochemical analysis of treated tumors verified apoptosis via caspase activation as a mechanism of OTSSP167 action. Further evaluation of downstream effectors via RNAseq and a reverse phase protein array (RPPA), using ACC cell lines matching the in vivo genetic diversity, demonstrated that OTSSP167 impeded cell cycle via G2/M arrest independent of TP53 status. In TP53 mutant lines, OTSSP167 enhanced DNA damage and inhibited protein synthesis. RSK1 was identified as a direct target of OTSSP167 activity in vitro. OTSSP167 also induced the G2/M checkpoint protein, WEE1, activation in all models, indicating an early adaptive response. Combining the WEE1 inhibitor AZD1775 with OTSSP167 significantly enhanced cytotoxicity in TP53 mutant lines, and reduced tumor growth in a TP53 mutant ACC model.

Conclusion

Together these findings establish the feasibility of using OTSSP167 in ACC, especially in TP53 mutant ACC tumors. In addition, this study demonstrates the possibility of targeting the early adaptive response subsequent to exposure to OTSSP167 treatment. Our findings provide strong rationale for a future phase I clinical trial in ACC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenocortical CarcinomaAdrenal Cortex NeoplasmsProtein Kinase InhibitorsHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysApoptosisTumor Suppressor Protein p53DNA DamageFemaleCell Proliferation

Stichwörter der Autor:innen

DNA damageOTSSP167adrenocortical carcinomacell cycle

Substanzen

Tumor Suppressor Protein p53Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Divisions of Endocrinology, Metabolism and Diabetes, University of Colorado, Aurora, CO 80045, USA.
  • Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, CO 80045, USA.
  • Medical Oncology, Department of Medicine, University of Colorado, Aurora, CO 80045, USA.
  • Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Research Service Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO 80045, USA.

ORCID-Profile: Nikita Pozdeyev, Margaret E Wierman, Katja Kiseljak-Vassiliades

Förderung

  • Veterans Affairs
  • NCI NIH HHS
  • Cancer League of Colorado
  • University of Colorado Cancer Center
  • NIH

Zitieren

APA

Kar, A., Banerjee, T., Pozdeyev, N., Holmstoen, T. B., Foust, L. J., Bagby, S. M., Pitts, T. M., Habra, M. A., Wierman, M. E., & Kiseljak-Vassiliades, K. (2026). Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. https://doi.org/10.1210/endocr/bqag091

Vancouver

Kar A, Banerjee T, Pozdeyev N, Holmstoen TB, Foust LJ, Bagby SM, et al. Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma. Endocrinology. 2026. doi:10.1210/endocr/bqag091

BibTeX
@article{Kar2026,
  author = {Kar, Adwitiya and Banerjee, Tapahsama and Pozdeyev, Nikita and Holmstoen, Tessa B and Foust, Lindsey J and Bagby, Stacey M and Pitts, Todd M and Habra, Mouhammed Amir and Wierman, Margaret E and Kiseljak-Vassiliades, Katja},
  title = {Comprehensive profiling of OTSSP167 action in adrenocortical carcinoma},
  journal = {Endocrinology},
  year = {2026},
  doi = {10.1210/endocr/bqag091}
}
Kostenlos starten →